The Use of Dabigatran in Elderly Patients

被引：149

作者：

Legrand, Matthieu ^{[1
]}

Mateo, Joaquim

Aribaud, Alice ^{[4
]}

Ginisty, Sixtine ^{[4
]}

Eftekhari, Pirayeh ^{[4
]}

Patrice Tran Ba Huy ^{[2
]}

Drouet, Ludovic ^{[3
]}

Payen, Didier

机构：

[1] Univ Paris 07, Lariboisiere Hosp, AP HP, Dept Anesthesiol & Crit Care, F-75475 Paris 10, France

[2] Univ Paris 07, AP HP, Ear Nose Throat Dept, F-75475 Paris 10, France

[3] Univ Paris 07, AP HP, Lab Immunol & Hematol, F-75475 Paris 10, France

[4] Univ Paris 07, Fernand Widal Hosp, AP HP, F-75475 Paris 10, France

来源：

ARCHIVES OF INTERNAL MEDICINE | 2011年 / 171卷 / 14期

关键词：

ATRIAL-FIBRILLATION; WARFARIN;

D O I：

10.1001/archinternmed.2011.314

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent approval by the US Food and Drug Administration (FDA) of dabigatran etexilate, an oral direct thrombin inhibitor, for the prevention of stroke in patients with atrial fibrillation will likely extend its administration in elderly patients. The risk of major overdosage of dabigatran etexilate in this population is, however, much increased owing to frequent renal function impairment, low body weight, drug interactions that cannot be detected with a routine coagulation test, and no antagonist available. We report herein 2 clinical cases, including 1 fatal case, illustrating our concern regarding the risk of bleeding events in elderly patients. Arch Intern Med. 2011;171(14):1285-1288

引用

页码：1285 / 1286

页数：2

共 6 条

[1]

Boehringer Ingelheim, 2010, PRAD DAB ET ADV COMM

[2]

Boehringer Ingelheim International GmbH, PRAD DAB ET SUMM PRO

[3] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[4] Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity [J].

van Ryn, Joanne ;

Stangier, Joachim ;

Haertter, Sebastian ;

Liesenfeld, Karl-Heinz ;

Wienen, Wolfgang ;

Feuring, Martin ;

Clemens, Andreas .

THROMBOSIS AND HAEMOSTASIS, 2010, 103 (06) :1116-1127

[5] Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial [J].

Wallentin, Lars ;

Yusuf, Salim ;

Ezekowitz, Michael D. ;

Alings, Marco ;

Flather, Marcus ;

Franzosi, Maria Grazia ;

Pais, Prem ;

Dans, Antonio ;

Eikelboom, John ;

Oldgren, Jonas ;

Pogue, Janice ;

Reilly, Paul A. ;

Yang, Sean ;

Connolly, Stuart J. .

LANCET, 2010, 376 (9745) :975-983

[6]

WHO Collaborating Centre for International Drug Monitoring Safety Monitoring of Medicinal Products, 2000, GUID SETT RUNN PHARM

← 1 →